MedTrace Logo

Canadian Pegvisomant Compassionate Study In Acromegalic Patients

NCT00151437 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-04-24

No results posted yet for this study

Summary

The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.

Conditions

Interventions

DRUG

Pegvisomant treatment

PROCEDURE

Medical History, demographics

PROCEDURE

Sign and symptoms: questionnaire

PROCEDURE

Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT

PROCEDURE

MRI

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2007-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00151437 on ClinicalTrials.gov